## Ilse Hoffman

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3612516/publications.pdf

Version: 2024-02-01

1163117 1474206 9 201 8 9 citations h-index g-index papers 9 9 9 314 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with InflammatoryÂBowel Disease under Combination Therapy. Journal of Pediatrics, 2022, 240, 150-157.e4.	1.8	10
2	A Clinical Perspective on the Dietary Therapies for Pediatric Eosinophilic Esophagitis: The Gap Between Research and Daily Practice. Frontiers in Immunology, 2021, 12, 677859.	4.8	4
3	Long-term outcome of immunomodulator use in pediatric patients with inflammatory bowel disease. Digestive and Liver Disease, 2020, 52, 164-172.	0.9	11
4	Neonatal factors predictive for respiratory and gastro-intestinal morbidity after esophageal atresia repair. Pediatrics and Neonatology, 2019, 60, 261-269.	0.9	17
5	Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease. Therapeutic Drug Monitoring, 2019, 41, 317-324.	2.0	26
6	Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2019, 68, 847-853.	1.8	36
7	Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease. Expert Opinion on Drug Safety, 2018, 17, 185-196.	2.4	15
8	Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2018, 12, 1316-1325.	1.3	47
9	Gastric fluid composition in a paediatric population: Age-dependent changes relevant for gastrointestinal drug disposition. European Journal of Pharmaceutical Sciences, 2018, 123, 301-311.	4.0	35